Spero Therapeutics, Inc. — Director's Dealing 2020

Sep 22, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2020-09-11

Reporting Person: Aquilo Capital Management, LLC (10% Owner)
Reporting Person: Aquilo Capital, L.P. (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.001 Par Value	4497142	Indirect

Footnotes

F1: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund that holds securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein.